WHOLE EXOME SEQUENCING OF HEMIPLEGIC MIGRAINE PATIENTS SHOWS AN INCREASED BURDEN OF MISSENSE VARIANTS IN CACNA1H AND CACNA1I GENES 203 9 Supplementary Information Supplementary Table 1 https://static-content.springer.com/esm/art%3A10.1007%2Fs12035-023-03255-5/ MediaObjects/12035_2023_3255_MOESM1_ESM.xlsx Supplementary Table 2 https://static-content.springer.com/esm/art%3A10.1007%2Fs12035-023-03255-5/ MediaObjects/12035_2023_3255_MOESM2_ESM.xlsx Acknowledgements: We greatly acknowledge the subjects who participated in this study. Author's Contributions: Omar Ibrahim, Aster VE Harder, Lisanne S Vijfhuizen, Rodney A Lea, Arn MJM van den Maagdenberg and Lyn R Griffiths contributed to the study conception and design. Whole exome sequencing and data collection were performed by Neven Maksemous, Heidi Sutherland, Nadine Pelzer, Irene de Boer and Gisela M Terwindt. Material preparation and analysis were performed by Omar Ibrahim, Aster VE Harder, Neven Maksemous, Lisanne S Vijfhuizen and Rodney A Lea. The first draft of the manuscript was written by Omar Ibrahim and Aster VE Harder with additional input from all co-authors. The final manuscript was read and approved by all authors. Funding: The authors disclose receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by: the Australian National Health and Medical Research Council (NHMRC-APP1122387) (LRG); a Migraine Research Foundation grant (2016), NY, USA (LRG); an Australian International Science Linkages grant (LRG); by infrastructure purchased with Australian Government EIF Super Science Funds as part of the Therapeutic Innovation Australia – Queensland Node project (LRG); the Centre of Medical System Biology (CMSB) in the framework of the Netherlands Genomics Initiative (NGI) 050-060-409 (AMJMvdM); and the European Community (EC) FP7-EUROHEADPAIN (no. 602633; AMJMvdM). Data availability: The data used and/or analysed during the current study are available from the corresponding author on reasonable request. Competing interests: GMT reports consultancy support from Novartis, Allergan/Abbvie, Lilly,
RkJQdWJsaXNoZXIy MTk4NDMw